EQT Life Sciences Leads $80M Series A for Mosanna's Sleep Apnea Nasal Spray

Whats Happening:

EQT Life Sciences is leading an $80 million Series A funding round for Mosanna Therapeutics, a Basel-based biotech company developing a nasal spray therapy for obstructive sleep apnea (OSA). The funding will support advancing Mosanna's MOS118 therapy through Phase 2 clinical trials. Mosanna has also appointed biotech veteran David Weber as CEO to guide the company's clinical development.

Key Moves:

• EQT Life Sciences leads $80M Series A funding for Mosanna Therapeutics

• Funding to advance MOS118 nasal spray therapy through Phase 2 clinical trials

• Biotech veteran David Weber appointed as CEO

By The Numbers:

• OSA affects nearly 1 billion people globally

• Majority of OSA patients are undiagnosed and underserved

• MOS118 is the first therapy to potentially restore natural airway reflex

Key Quotes:

• "What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue" - Daniela Begolo, Managing Director at EQT Life Sciences

• "Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life," - David Weber, CEO of Mosanna

Bottom Line:

EQT Life Sciences' investment in Mosanna Therapeutics represents a significant step in addressing the unmet needs of OSA patients. By developing a non-invasive nasal spray that aims to restore natural airway control, Mosanna could potentially revolutionize OSA treatment, offering a more comfortable and effective alternative to current mechanical solutions.

Read Full Article